@n-ABLE
The e-newsletter for the Indian Biotech industry

www.ableindia.in

January 2026 | Issue 0022

Wish you all a very Happy New Year!



Dear Members, Colleagues and Friends,

As we step into the New Year 2026, I am happy to inform all our members that 2025 has been very good year for ABLE as well as our industry. I would like to share some of the highlights from ABLE perspective:

VOICE FOR BT: This has **become** an **international event**, with ASEAN participation. All credit goes to our **GM, Dr. Balasubramanya** for the efforts, and we hope to soon extend this event to EU and US! Appreciate both **Ms**. **Pavana Praveen** and **Ms. Indrila Sengupta** to have stepped up to meet international standards in conducting this event.

BEST AWARDS: We have managed to continue the event, with four zonal rounds and providing cash prizes to the winners in each region apart from Internship opportunities from our member companies, to encourage them to take up the path of entrepreneurship with their award-winning ideas. However, the **'best' is yet to come** out of this event. This will be a specific focus to step-up in 2026.

BIOECONOMY CONCLAVE 2025: The event **went very well** and was well appreciated by all. Also, we had good sponsorship support, and the sessions were well curated thanks to the **active participation from our GB members.** In the 2026 edition slated for February 24 we would like to do it even better.

BIOECONOMY REPORTS: All **credit to Mr. Narayanan Suresh, Dr. Balasubramanya and Mr. Srinivas Chandan Rao**. ABLE has produced state level BioEconomy Reports for Karnataka, Gujarat, Kerala and Chhattisgarh in 2025. The all-India Report and a BioVision Report for Tamil Nadu are under preparation. We have requests coming from the States on the report for their regions. While the credibility of the reports has been commendable, we realize the **need for stepping up and strategizing the contents**.

US BIO: **2025** event at Boston was very **successful at the 'INDIA PAVILION' with the presence of Dr. Kiran Mazumdar-Shaw**, **Dr. Jitendra Kumar and State Government participation**. Appreciate the entire ABLE secretariat team for all their involvement in organizing the event. In **2026** we will have a **larger** for the **'INDIA PAVILION**' (5000 SFT) with strategic understanding with 3SMG Events. We have all the indications for active participation from DBT/BIRAC, more State Government participation and presence of central Ministers.

BENGALURU TECH SUMMIT 2025: **ABLE played an important role under the Chairmanship of Dr. Vijay Chandru** in conducting the BT track and our GB members had the opportunity to curate most of sessions. We were also entrusted the responsibility to identify SMART BIO AWARDEES

OUTREACH ACTIVITIES: **The Secretariat has collaborated with** various **international organizations** @ Scotland, UK, USA, Canada and Japan and signed MoUs to support startups. This is a crucial initiative to support our entrepreneurs to establish international collaborations and investment opportunities. A few delegation visits have been successfully organized.

STAKEHOLDER ENGAGEMENT: We have had **close interactions** with **DBT/BIRAC** especially in the **BioE3 roll out** and other sector specific initiatives. We have also been entrusted to establish a **DBT portal on** various **imports** in the Biotech segment, which will give clear statistics on the actual import volume of various products into India. This will be an eye opener for local entrepreneurs and startups to focus on the opportunities. This will be launched in early 2026.

Niti Aayog has entrusted the responsibility to ABLE to prepare the road map for BioEconomy projected to reach $ 1.2 Trillion by 2047. This was supported by a strong committee which had Dr Kiran, Dr Vijay Chandru and Dr P M Murali and me from ABLE. This will be launched soon.

I would also like to inform that Mr. Narayanan Suresh after a 9-year stint as **COO** at ABLE, decided **to formally retire**. We very much appreciate his valuable contribution and support in managing the organization with his vast experience during his stint. We are very happy **Mr. Narayanan Suresh** has agreed **to continue** to support us **as an Advisor**.

ABLE AGM: We had a successful AGM with good participation from our GB members and other members. We passed all the statutory requirements. We had the privilege of listening to Dr. Kiran's speech on the way forward for ABLE and the importance of involvement of all members.

Dr Murali conveyed, the Council of Presidents decision, on the importance of the existing GB members continuing for one more year until March 2027, in order to ensure all the initiatives taken so far are completed, before we hand over to the new team. This is critical for the GB members to work together in achieving this objective and we seek all your support.

WISHING YOU AND YOUR FAMILIES A VERY HAPPY AND PROSPEROUS NEW YEAR!!

On behalf of ABLE OFFICE BEARERS (Mr. Krishnan G S, Dr. Deepanwita Chattopadhyay, Dr. Ezhil Subbian & Mr. Ravi Bhola)

IN THIS ISSUE

'India Pavilion' at BIO International Convention 2026 in San Diego, USA

The **BIO International Convention & Exhibition** continues to be the world's most influential biotechnology gathering, bringing together global leaders from biopharma, biotech startups, investors, academia, government agencies, and innovation-driven enterprises. Each year, BIO sets new benchmarks with its scale, impact, and global participation—featuring thousands of companies, 75+ countries, and tens of thousands of partnering meetings that catalyze collaborations worldwide.

We are delighted to share that **ABLE** will once again be organizing the **'India Pavilion'** at the **BIO International Convention 2026**, scheduled from **22–25 June 2026** in **San Diego, California, USA**. This year, ABLE is hosting an expanded and more impactful 'India Pavilion', spread across **5000 SQF** at **Booth Nos. 3351 and 3551**, in collaboration with **3SMG Private Limited**.

Booth No. 3351 has been **exclusively earmarked for ABLE members and previous exhibitors**, while **Booth No. 3551** is designated for **3SMG clients**. The India Pavilion is

IN THIS ISSUE

strategically located to **ensure maximum visibility, high footfall, and meaningful engagement with global delegates**.

The Proposal-cum-Information e-Booklet provides complete details on:

- India Pavilion layout and graphical representations
- Booth categories, sizes, entitlements, and pricing
- Exhibitor badges and partnering access
- Payment terms and deadlines
- Presentation & rapid-fire chat opportunities at the India Pavilion
- Exclusive discount codes for ABLE Members
- Government market-access reimbursement options

As always, **ABLE will manage the complete booth set-up and logistics in San Diego**. Confirmed exhibitors must provide only the graphic panels and logo files as per the specified formats and timelines. We would be pleased to assist you in selecting the most suitable booth category and guide your team through the registration and participation process. We look forward to welcoming your esteemed organisation as a valued exhibitor in the India Pavilion at BIO 2026, and to building on the momentum, partnerships, and successes from previous editions. Reach out to Dr. Balasubramanya S, General Manager, ABLE for detailed discussion (*Email: gm@ableindia.org.in , Mobile: 99000 48833*)

Click here for more information
https://drive.google.com/file/d/1Pq3Rz_9uofiu6ocizZCq7fd3er821l_h/view

---

'voice for BT' International Finals 2025

The **International Finals of 'voice for BT' 2025** were successfully held on **5th December** at **The Chancery Pavilion, Bengaluru**, bringing together some of the brightest student voices in biotechnology from across India and ASEAN. The event showcased how young scientists are shaping the future of biotech through powerful ideas, clear communication and scientific depth.

ABLE successfully conducted the zonal rounds of 'voice for BT' in India as well as the first ever International edition during the past two months hosted by our Regional Academic Partners:

- Amity University, Noida in the North zone
- DY Patil Deemed to be University, Mumbai in the West zone
- KIIT University, Bhubaneswar in the East zone
- Sastra Deemed to be University, Thanjavur in the South zone
- Universiti Putra Malaysia for the International (ASEAN) edition

IN THIS ISSUE

Aishwarya Mudgal from Amity University, Punjab was the winner.
Aishwarya delivered the winning address on “Climate-Resilient Agriculture and its Role in Addressing Farmer Distress,” offering a compelling perspective on sustainability, resilience and food security.

Sipra Mishra from KIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar was the Runner-up.
Sipra impressed the jury with her talk on “The Importance of AI in Drug Discovery and Diagnosis,” highlighting the transformative role of artificial intelligence in modern healthcare.

Both finalists demonstrated outstanding clarity of thought, communication excellence and deep scientific insight, making the International Finals truly memorable.

Participants delivered thought-provoking speeches across three major contemporary biotech themes:

- The importance of AI in drug discovery and diagnosis
- Climate-resilient agriculture to address farmer distress
- Better utilisation of biomass and municipal solid waste

Across the zonal rounds, several outstanding performances were delivered on “Better Utilisation of Biomass & Municipal Solid Waste,” reflecting the growing emphasis on sustainability, circular economy and waste-to-value innovation within the biotech ecosystem.

We extend our heartfelt thanks to our India Zonal Round sponsors **Novonesis** and **Yokogawa**, and to **Biocon Biologics** and **Amano Enzyme** for supporting the first-ever International (ASEAN) edition of ‘voice for BT’.

IN THIS ISSUE

We were honoured to have **Prof. (Dr.) B. S. Satyanarayana**, Vice-Chancellor, Dayananda Sagar University, as our Guest of Honor. Our sincere appreciation to our distinguished jury panel for their thoughtful evaluation and expert guidance: **Suchitra Tripathy** (Novonesis), **Shreya Sanghvi Malik** (Wadhwani Foundation), **Dr. Jayashree (Jay) Aiyar** (Syngene International Limited) and **Dr. Ashish Paradkar**. We also thank **Mr. Krishna Mohan Puvvada** (Novonesis) for joining us online and inspiring participants, and extend special appreciation to **Sanjeev Neelappa** (Yokogawa) and **Sowmya Shresth** (Novonesis) for their presence and continued organisational support.

A big thank you to every participant for their passion, preparation and courage.

'voice for BT' International 2025 (ASEAN)

The **first-ever International (ASEAN) Edition of *'voice for BT' 2025***, the intercollegiate public speaking competition for biotechnology students was successfully held on **27th November 2025** at **Universiti Putra Malaysia, Kuala Lumpur**.

This landmark edition marked an important step in expanding the *'voice for BT'* platform beyond India, bringing together talented young speakers from across the ASEAN region. Participants demonstrated exceptional clarity, confidence, and scientific insight as they articulated complex biotechnology concepts with purpose and precision. The event highlighted the growing importance of **science communication** in shaping the next generation of biotechnology innovators, researchers, and industry leaders.

The **Winner** was **Roshvin Kailashnath Pillai** from Mahsa University, Bandar Saujana Putra, Selangor, Malaysia. The **First runner-up** was **Imaan Nabila Binti Sahrin** from Faculty of

Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang and the **Second runner-up** was **Nancy Novmia A/P M Marianyagam** from Universiti Putra Malaysia, Klang, Selangor.

We extend our sincere gratitude to **Biocon Biologics** and **Amano Enzyme** for their invaluable support in making this international edition a success. We also thank the **Universiti Putra Malaysia organising team** for their excellent coordination and warm hospitality.
Our heartfelt appreciation goes to our distinguished jury members—**Dr. Alolika Chakrabortti (Biocon Biologics), Walaiporn Timbuntam (Amano Enzyme), Lakshmi Narasimhan (Novonesis), and Moses Christopher (Valent BioSciences)**—for their time, expertise, and thoughtful feedback, which greatly enriched the experience for all participants. We also acknowledge **Joe Sian (Biocon Biologics)** for joining us as a special invitee and for his support of the initiative. Congratulations to all participants for their enthusiasm, curiosity, and outstanding performances. This ASEAN edition marks a significant new chapter for *Voice for BT*, strengthening its role as a platform that connects **talent, innovation, and scientific communication across borders**.

ABLE as Ecosystem Partner at Bio Connect 3.0 – International Life Science Conclave & Expo

Kerala State Industrial Development Corporation Ltd. KSIDC | bio 360 Life Sciences Park three sixty degrees of innovation | KERALA LIFESCIENCES INDUSTRIES PARKS (P) LTD Subsidiary of Kerala State Industrial Development Corporation Limited | Invest Kerala NATURE. PEOPLE. INDUSTRY.

BIO CONNECT 3.0

9 - 10 OCTOBER, 2025

ABLE was proud to host a high-impact session on **"Kerala Bioeconomy: Potential and Opportunities"** at **BioConnect 3.0 – International Life Sciences Conclave & Expo**, held in Kerala. The session brought together policymakers, industry leaders and ecosystem enablers to explore how Kerala can strengthen its position as a leading biotechnology and life sciences hub.
The discussion was expertly moderated by **Narayanan Suresh, Advisor, ABLE**, and featured an eminent panel led by **Krishnan G S, Hon. President, ABLE**, alongside:

- **Vishnuraj, IAS**, Managing Director, Kerala State Industrial Development Corporation (KSIDC)
- **Prof. A. Sabu**, Member Secretary, Kerala State Council for Science, Technology and Environment (KSCSTE)
- **Taranjeet Kaur**, Senior Manager, Biotechnology Industry Research Assistance Council (BIRAC)
- **Dr. Manbeena Chawla**, Executive Editor, BioSpectrum India

The session focused on **doubling the contribution of the bioeconomy to Kerala's GSDP from 5% to 10%**, the strategic importance of establishing a **large nutraceutical cluster**, and the critical role of **policy, innovation and industry collaboration** in accelerating growth.
The engaging and forward-looking dialogue highlighted **Kerala's strong potential in biotechnology, entrepreneurship and sustainable development**, reaffirming the state's readiness to emerge as a powerful bioeconomy hub in India.

Kerala BioEconomy Report 2025 released at BioConnect 3.0

The **Government of Kerala** officially released the **Kerala BioEconomy Report 2025** at **BioConnect 3.0 – International Life Sciences Conclave & Expo**, marking a major milestone in the state's life sciences and biotechnology journey. The report was prepared by **ABLE – Association of Biotechnology Led Enterprises** for **Kerala Life Sciences Industries Park (KLIP)**, a subsidiary of the **Kerala State Industrial Development Corporation (KSIDC)**.

The report positions **Kerala as a national leader in sustainable bio-based growth**, estimating the state's bioeconomy at **US $7.53 billion (₹62,000 crore)** — accounting for **4.25% of India's total bioeconomy** — and projecting its expansion to **US $11–12 billion (₹100,000 crore) by 2030**. This growth is being driven by key sectors including **Ayurveda, biotechnology, marine bioresources, nutraceuticals and bio-industrial innovation**, supported by a rapidly expanding ecosystem of **over 300 life science startups**, alongside strong research institutions and incubators across the state.

The report was formally released by **Shri P. Rajeev**, Hon'ble Minister for Law, Industries and Coir, Government of Kerala, in the presence of senior national and international leaders, including **Shri A. P. M. Mohammed Hanish, IAS**, Principal Secretary (Industries), Government of Kerala; **Shri Rajesh Kumar Pathak**, Secretary, Technology Development Board, Government of India; **Shri Timothy Rowe**, CEO, Cambridge Innovation Center (CIC) and Co-founder, LabCentral, Boston; **Shri Vishnuraj, IAS**, Managing Director, KSIDC; **Dr. Praveen K S**, CEO, KLIP; **Narayanan Suresh**, Advisor, ABLE; and **Dr. Balasubramanya S**, General Manager, ABLE. The launch of the **Kerala BioEconomy Report 2025** underscores Kerala's growing global relevance as a hub for **innovation-driven, sustainable and inclusive bio-based economic growth**.

ABLE as an Association Partner at Bengaluru Tech Summit 2025

The Bengaluru Tech Summit 2025 concluded successfully as a premier platform for innovation, collaboration, and technology-driven growth. **ABLE was proud to participate as the Association Partner**, playing a pivotal role in shaping high-impact conversations around the future of biotechnology and the bioeconomy. ABLE curated a powerful lineup of discussions at the LifeStage (DigiHealth & Biotech), bringing together industry leaders, innovators and policymakers to examine the future of biotechnology across three high-impact domains.

The session on **“Emerging Technologies Shaping the Future of Biotechnology”,** was chaired by Mr. G S Krishnan, Hon. President, ABLE. The session featured inspiring lead talks by Dr. Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics and Dr. Debjani Ghosh, Distinguished Fellow, NITI Aayog. The session brought together leading thinkers and innovators to explore how AI, data science, and cutting-edge research are redefining the boundaries of biotechnology. From healthcare breakthroughs to sustainable solutions, the discussions highlighted how the convergence of technology and biology is enabling a smarter, healthier, and more sustainable future.

The panel on **“Bio-E3 and Bio-Manufacturing”** moderated by Dr. P M Murali, President, ABLE Council of Presidents and CMD, Jananom, examined how innovation, education, and entrepreneurship are shaping the next phase of India’s bioeconomy. Panelists emphasized the vital role of academia in building a skilled, research-ready workforce to meet the growing demands of biotechnology and advanced manufacturing. The discussion also addressed key financial and operational challenges, including grant inflation and the need for sustainable funding models to support long-term research and industry collaboration. The session underscored that strong alignment between academia, industry, and policy will be critical to scaling India’s biomanufacturing capabilities globally.

The session on **“Agri-Biotech and Food Innovation”**, moderated by Dr. K K Narayanan, Founder & Managing Director, Sthayika Seeds Pvt., explored how biotechnology is driving a new era of growth in agriculture and food systems. Experts discussed how emerging technologies can make food production more resilient, sustainable, and inclusive, addressing challenges around productivity, nutrition, and environmental balance. The panel highlighted the importance of leveraging innovation to strengthen India’s leadership in agri-biotech on the global stage.

The session on **"Environmental Biotechnology and Bio-remediation"**, moderated by Mr. G S Krishnan, Hon. President, ABLE, focused on how scientific innovation is reshaping ecological sustainability. Panelists examined changes in the global biomass of mammals since 1850, the growing role of microbial production, and breakthroughs such as carbon-fixing *E. coli* for carbon capture. The discussions also covered practical solutions including biodegradation of caffeine into valuable bioactive compounds and Praj Industries' technologies such as HaloSOL for high-COD and high-TDS effluents and advanced coke-oven wastewater treatment. The session concluded with a powerful message: waste is not the end of a product's life, but the beginning of another value chain, reinforcing the importance of circular economy and regenerative bio-solutions.

ABLE's participation at Bengaluru Tech Summit 2025 reaffirmed the central role of biotechnology in India's innovation landscape. By bringing together industry pioneers, policy leaders and technology visionaries, ABLE continues to foster dialogue, collaboration and investment that will drive sustainable growth, healthcare innovation and global competitiveness for India's biotech sector.

Smart Bio Awards 2025

ABLE was proud to have supported the award selection process and ensured a fair and comprehensive evaluation to identify the most deserving companies. This platform has been an incredible opportunity for biotech companies from Karnataka to gain visibility and recognition for their pioneering work on a global stage and we couldn't be more proud of the talent and innovation showcased this year. A big congratulations to all the winners and participants of the Smart Bio Awards 2025 at Bengaluru Tech Summit.

Smart Bio Awards Winners

Award Category	Awardee
Startup of The Year	MicrobioTx Health Pvt. Ltd., Bengaluru
Innovator of the Year	InnAccel Technologies Pvt. Ltd., Bengaluru
Women Entrepreneur of the Year	Ms. Payal Patel, Co-Founder & CEO, Agropak Pvt. Ltd., Bengaluru
Best Campus Company of the Year	Theraxcel Healthcare Pvt. Ltd., Mangaluru
Startup of the Year (Beyond Bengaluru)	SGB Agroindustries, Sri Gowri Bhargava Pvt. Ltd, Chikamagaluru

ABLE participated at Maharashtra Bio-Next Roundtable

ABLE was honoured to participate in the Maharashtra Bio-Next Roundtable at the Bengaluru Tech Summit 2025, a high-level dialogue convened by the Government of Maharashtra – Industries Department to advance the state's ambition of becoming a global hub for health, biotechnology and bio-manufacturing.

Maharashtra currently contributes over one-third of India's biopharma output and is home to more than 1,600 biotechnology startups, making it one of the country's most powerful innovation engines. The Bio-Next Mission aims to further accelerate this leadership through a comprehensive growth strategy that includes a forward-looking biosciences policy, the creation of dedicated bio-investment zones, a proposed ₹1,000-crore Bio-Innovation Fund, and deeper industry–academia–government collaboration.

During the roundtable, ABLE shared strategic inputs on policy frameworks, biomanufacturing capacity, and innovation pathways that can help unlock the next phase of growth and strengthen Maharashtra's role in India's $165-billion bioeconomy. ABLE looks forward to continuing its close engagement with the Government of Maharashtra under the Bio-Next initiative, working together to create new opportunities for startups, investors and innovators and to drive globally competitive, sustainable bio-based growth.

ABLE webinar on "Engineering Reliability: Tackling Variability in Biopharma Raw Materials and Ingredients"

ABLE, with the support of BASF Pharma Solutions, hosted a high-impact webinar focused on advanced biopharma ingredients for biologics, biosimilars, and cell & gene therapies. The session brought together experts to highlight how high-quality, consistent raw materials are critical to improving cell culture performance, process stability and final product quality. The webinar was opened by **Dr. Balasubramanya S**, General Manager, ABLE, and **Dr. P. M. Murali**, President, ABLE Council of Presidents, who set the context around India's fast-growing biologics and biosimilars ecosystem and the need for high-quality, consistent and compliant raw materials in this highly regulated sector.

Dr. Aditi Poddar, Business & Technical Services Manager – South Asia, BASF Pharma Solutions, provided an overview of BASF's global footprint. She highlighted BASF's extensive pharma and biopharma portfolio, including excipients, APIs, lipid systems, solubilizers and

biologics-grade surfactants for upstream, downstream and formulation stages. The technical core of the session was led by **Dr. Nadya Morales-Cummings**, Global Technical Marketing Manager – Biopharma Ingredients, BASF Pharma Solutions (USA). She addressed one of the biggest challenges in biologics manufacturing: raw-material variability, particularly in surfactants used in chemically defined cell-culture media.

The session highlighted India's strong opportunity in biosimilars, CMOs, and emerging cell & gene therapies, as many blockbuster biologics go off-patent globally. BASF and ABLE emphasized their commitment to supporting Indian startups, manufacturers and academic institutions through Product sampling and technical support from BASF's Mumbai lab, Collaboration on process optimization and formulation and Access to global R&D and application expertise. The webinar underscored that bioprocess performance is no longer driven by cells alone ingredients matter. With scientifically optimized surfactants, digital tools, and sustainability-driven manufacturing, BASF is helping Indian biopharma players achieve higher yields, better consistency and faster scale-up.

ABLE and BASF will continue this dialogue through future knowledge-sharing sessions, case studies and industry collaborations.

ABLE supports BIO-X India - Expo & Conference 2026

We are pleased to inform you that **ChemTECH** is organizing the **Bio-X India - Expo & Conference 2026**, **powered by Association of Biotechnology Led Enterprises - ABLE**, from **3rd – 6th February 2026** at the Bombay Exhibition Centre, Goregaon, Mumbai. The event will run concurrently with the 52nd Year of ChemTECH World Expo & Conferences.

The four-days event has Exhibition and a one-day conference themed **"Reimagining the Future of Biotech in India"**. It will bring together the entire biotechnology value chain to showcase innovation, drive partnerships, and promote high-quality growth in the sector and beyond. The conference will bring together over 1,000 exhibitors and 26,000 industry visitors from more than 50 countries, offering unmatched opportunities to connect with both suppliers and buyers across multiple user industries. Alongside the exhibition, a series of concurrent technical conferences covering EPC, Specialty Chemicals, Agrochemicals & Fertilizers, Water & Environment Services, Refining & Petrochemicals, Industrial Automation, Pumps, Valves & Fittings, HSE and Surface Engineering will drive knowledge exchange and collaboration. This makes Bio-X India a truly high-value platform for business development and networking, not only for the biotechnology sector but also for organizations delivering bio-based solutions across diverse industrial domains.

For more information, please reach out to Dr. Balasubramanya S, General Manager, ABLE for detailed discussion (*Email: gm@ableindia.org.in , Mobile: 99000 48833*).

Click here to view the Brochure.


Pursuing
Infinite
Opportunities
Association of Biotechnology Led Enterprises
SAVE THE DATE
BIO ECONOMY
CONCLAVE 2026
24 FEBRUARY 2026
TAJ MG Road, Bengaluru
Stay tuned www.bioeconomy.in

MEMBER NEWS

Biocon to Integrate Biocon Biologics to Create a Unified Global Biopharmaceutical Leader

Biocon group has announced a strategic corporate action to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary into Biocon Limited, subject to applicable approvals.
Biocon Limited is constituting a Governance Council chaired by Dr Kiran Mazumdar-Shaw and a Transition and Integration Management Committee, led by Dr Shreehas Tambe, CEO & MD of Biocon Biologics, to ensure a seamless integration.
The Strategy Committee, constituted in May 2025, undertook a comprehensive evaluation of multiple strategic options for Biocon Biologics Limited, including an IPO and a merger with Biocon Limited. After careful consideration of key parameters such as strategic alignment, sectoral dynamics, shareholder value creation, and other relevant data, the Committee concluded that full integration of BBL with Biocon Limited and making BBL a wholly owned subsidiary of Biocon Limited through the acquisition of minority stakes offers the most efficient and value-accretive path forward.

Under the proposed transaction,

1. Biocon Limited will acquire the remaining stake in BBL from Serum Institute Life Sciences (Serum), Tata Capital Growth Fund II (Tata Capital) and Activ Pine LLP (Activ Pine) through a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares, at a share price of ₹ 405.78 per Biocon share; valuing BBL at $ 5.5 billion.
2. Further, Biocon will acquire the residual stake held by Mylan Inc. (“Viatris”) for a total consideration of $ 815 million, of which $ 400 million will be payable in cash and $ 415 million through a share swap of 61.70 Biocon shares for every 100 Biocon Biologics shares at a share price of ₹ 405.78 per Biocon share.
3. The swap ratios have been approved by the Board based on independent valuations by EY.

The Board has also approved raising additional capital, of up to ₹ 4500 crore ($ 500 million) through Qualified Institutional Placement (QIP), subject to shareholder approval. The proceeds of the QIP will be largely utilised towards the cash component payable to Viatris.

The integration process is expected to be completed no later than March 31, 2026. This integration marks a pivotal step in combining the businesses to leverage the global commercial infrastructure, simplifying the corporate structure and strengthening Biocon’s global position to lead in diabetes, oncology, and immunology — therapeutic areas that together account for nearly 40% of global pharmaceutical revenues. As the only company operating globally with both biosimilar insulins and generic versions of complex peptides, including GLP-1s, Biocon is uniquely poised to address the rapidly expanding ‘diabesity’ market.

Mr Siddharth Mittal and Dr Shreehas Tambe will continue in their roles as CEO & Managing Director at Biocon Limited and BBL, respectively, until completion of the integration process.

Post the integration and upon execution of the necessary documentation, receipt of approvals from the Nomination & Remuneration Committee and the Board, Dr Shreehas Tambe will take on the role of CEO & Managing Director and Mr Kedar Upadhye the role of Chief Financial

Officer of the combined business. Mr Siddharth Mittal, CEO & MD, Biocon Limited, will transition into a leadership role within the Group.

Commenting on the corporate action, Dr Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said: "The integration of BBL into Biocon Limited represents the next chapter in our evolution. Strategically, Biocon will be one of the few companies offering both biosimilars and generics at a global scale. As the only company with biosimilar insulins and generic GLP1 peptides, Biocon is uniquely positioned to comprehensively address the needs of patients living with diabetes. Together with our combined oncology and immunology portfolios, this creates a differentiated offering addressing the world's most pressing healthcare needs. I am also pleased to announce that Dr Shreehas Tambe will lead the Transition and Integration Management Committee and will take over as the CEO & MD of the combined business, subject to requisite approvals. His 28 years of experience with the Biocon Group will be invaluable as we advance our mission to make lifesaving medicines affordable and accessible to patients worldwide."

This integration enables Biocon to harness the combined strengths of its generics and biosimilars businesses across 120+ countries. Biocon Biologics ranks among the Top 5 global biosimilar players by revenue, with 10 commercialized products across key markets, while Biocon's generics business offers over 90 products.

Quarterly Results

Biocon Operating Revenue at ₹ 4,296 Cr, Up 20%e 11-Nov

EBITDA at ₹ 928 crore; Up 29%; and PBT (before exceptional items) at ₹ 183 Cr, Up 153%
ABLE Patron gold member, **Biocon Limited** has announced its consolidated financial results for the fiscal second quarter ended September 30, 2025.

*"Business performance in **Q2 FY26** remained strong, with operating revenue up **20%** year-on-year to **₹ 4,296 crore**, driven by robust growth in **Biosimilars**, improved momentum in **Generics**, and a steady contribution from the **CRDMO** segment. **EBITDA** grew **29%** to **Rs 928 crore**, while Profit before Tax **(PBT),** excluding exceptional items, surged **153%** to **₹ 183 crore**.*
"With the Board approval of the settlement of structured debt obligations, we will strengthen our balance sheet, enhance financial flexibility, and improve profitability.
"Our partnership with the State of California through Civica Inc. under the CalRx initiative, marks a landmark step in expanding affordable insulin access in the U.S., with potential to extend to other states.
*"With a resilient foundation, differentiated portfolio, and clear strategy, we are well positioned to sustain growth and deliver long-term value to our stakeholders," said **Dr Kiran Mazumdar-Shaw, Chairperson, Biocon Group***

Biocon Generics

*"The **Generics** business continued its steady performance in Q2 with a growth of **24%** driven primarily by an uptick in recently launched products in the U.S. and EU, as well as growth in the generic formulations base business, and the API business.*
*"A key highlight of this quarter was the inauguration of Biocon's **first OSD manufacturing facility in the United States**, a significant step towards expanding access to our vertically*

integrated portfolio for patients in the region. We commenced filings for Semaglutide (gOzempic) in various markets, including Canada and Brazil," commented Mr ***Siddharth Mittal, CEO & Managing Director, Biocon Limited***

Biocon Biologics

*"****Biocon Biologics*** *delivered a strong performance in Q2 FY26, achieving* ***25%*** *year-on-year revenue growth and an over* ***40%*** *increase in* ***EBITDA****. Sequentially, revenues grew* ***11%****, driven by market share expansion in key therapy areas and successful new product launches.*
In the U.S., we continue to expand access to biosimilars by leveraging the strength of our commercial platform. In FY26, we launched four biosimilars across key global markets and remain on track for the bDenosumab launch," said Dr ***Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited****.*

Syngene International

"Our Q2 results reflect strong underlying revenue growth in research services, which has offset the expected inventory correction in biologics manufacturing. We continue to maintain our annual guidance for FY26.
"We are also building a GMP bioconjugation suite at our Bengaluru biologics facility, which will enable end-to-end manufacturing of Antibody Drug Conjugates (ADCs), positioning us among a select group of CRDMOs offering comprehensive ADC services," commented Mr ***Peter Bains, CEO & Managing Director, Syngene International Limited.***

Praj announces Q2 FY26 results

Revenue at ₹ 8,416.3 million; PAT at ₹ 192.8 million

Praj Industries (Praj), has announced its unaudited financial results for the quarter ended Sept 30, 2025

Performance Review for Q2 FY26 - Consolidated:

- Income from operations stood at ₹ 8,416.3 million (Q1 FY26: ₹ 6,402.0 million; Q2 FY25: ₹ 8,161.9 million)
- PBT is at ₹ 296.1 million for the period (Q1 FY26: ₹ 96.1 million; Q2 FY25: ₹ 744.4 million)
- PAT is at ₹ 192.8 million (Q1 FY26: ₹ 53.4 million; Q2 FY25: ₹ 538.3 million)
- Order intake during the quarter ₹ 8,130 million (Q1 FY26: 7,950 million; Q2 FY25: ₹ 9,210 million) Performance Review for H1 FY26 - Consolidated:
- Income from operations stood at ₹ 14,818.4 million (H1 FY25: ₹ 15,153.3 million)
- PBT is at ₹ 392.2 million for the period (H1 FY25: ₹ 1,814.8* million).
- PAT is at ₹ 246.2 million (H1 FY25: ₹ 1,380.1* million)
- Order intake ₹ 16,080 million (H1 FY25: ₹ 18,090 million) *Includes Exceptional items ₹ 281.6 million

Commenting on the Company's performance, Mr. Ashish Gaikwad, MD, Praj Industries said, "Our unwavering focus on execution enabled us to deliver Q2FY26 performance despite continued challenges in the external business environment- particularly in the domestic ethanol segment and in the international market due to US tariff headwinds. We remain committed to focusing on controllable factors in the second half of FY26 and our vision to deliver long-term growth aspirations."

Lupin Quarterly Results

These are the highlights of Lupin for the quarter ending September 30, 2025. **Financial Highlights – Consolidated IND-AS**

- Gross Profit was ₹ 50,066 million compared to ₹ 38,071 million in Q2 FY2025, with a gross margin of 73.3%.
- Personnel cost was 16.2% of sales at ₹ 11,056 million compared to ₹ 10,075 million in Q2 FY2025.
- Manufacturing and other expenses were 29.0% of sales at ₹ 19,796 million compared to ₹ 16,670 million in Q2 FY2025.
- PBT at ₹ 20,070 million at 29.4%, up 90.3% YoY from ₹ 10,549 million in Q2 FY2025.
- Investment in R&D for the quarter was ₹ 5,091 million (7.5% of sales).

Balance Sheet highlights

- Operating working capital was ₹ 77,304 million as on September 30, 2025.
- Capital Expenditure for the quarter was ₹ 3,474 million
- Net Debt as on September 30, 2025, stands at ₹ 16,646 million
- Net Debt Equity as on September 30, 2025, stands at -0.08.

Mr. Nilesh Gupta, Managing Director, Lupin Limited said "We are delighted to present one of our strongest performances ever in this second quarter of FY26. We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the U.S., emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong FY26".

Biosimilars Update

Global biosimilars market to reach $ 73 billion in 2030, predicts Fortune Business Insights

The global biosimilars market is projected to grow to $ 73.03 billion by 2030, registering a CAGR of 17.3% per cent in the last 7 years. The market was valued at $ 35.05 billion in 2025, $ 23.96 in 2023 and $ 20.44 billion in 2022, according to a report from Fortune Business Insights on December 29, 2025.

Regulatory authorities in developed countries are now approving biosimilars at a fast rate due to availability of more precise guidelines. US has approved an estimated 85 biosimilars by the end of 2025, compared to 45 in 2023. Europe has approved more than 86 biosimilars in the last decade.

Notable approvals by US FDA in 2025 include:

- Denosumab: Several biosimilars (e.g., Osenvelt, Stoboclo, Ospomyv, Xbryk, Bomyntra, Conexxence, Osvyrti, Jubereq) for Prolia/Xgeva were approved, with many receiving interchangeability designations.
- Tocilizumab: Celltrion's Avtozma (tocilizumab-anoh) was approved for Actemra.

- Omalizumab: Sanofi's Omlyclo was approved for Xolair.
- Ustekinumab: Alvotech's Selarsdi and Sandoz's Enzeevu were approved for Stelara, with some provisional interchangeability.
- Pertuzumab: Poherdy (pertuzumab-dpzb) was approved in November 2025 for Perjeta.

Regulators, such as the European Medicine Agency (EMA), the U.S. Food and Drug Administration (FDA), and Health Canada (HC) have developed stringent regulatory guidelines for the assessment and approval of these products in terms of their physical characteristics, chemical composition, and clinical characteristics. This has enabled rapid drug development and approval, as well as increased market access and cost-effectiveness.

Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg™ (P egfilgrastim-unne)

ABLE member, Lupin Limited (Lupin), announced in December 2025 that the United States Food and Drug Administration (U.S. FDA) has approved Armlupeg™ (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe, as biosimilar to Neulasta® (pegfilgrastim) 6 mg/0.6 mL injection. The product will be manufactured at Lupin's Biotech facility in Pune, which was inspected by the U.S. FDA prior to approval.

Armlupeg™ is indicated for:

- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation.

"We are proud to achieve the FDA approval for our first biosimilar, Pegfilgrastim. This step marks a pivotal step in Lupin's ongoing commitment to providing more affordable, accessible medicines to U.S. patients. We look forward to introducing a robust portfolio of biosimilars over the next few years, which will help improve the quality of care for the communities and patients we serve," said Ms **Vinita Gupta, CEO, Lupin**.

Mr Nilesh Gupta, MD, Lupin, said, "Our integrated biologic capabilities encompass the entire spectrum, from initial cell line development to upstream/downstream process optimization and clinical development. This, coupled with our state-of-the-art biologic facility that has now been approved by every major regulatory body, ensures that we deliver biosimilars that meet the highest global quality standards while achieving the scale necessary for global affordability."

"We are pleased to have obtained approval for Pegfilgrastim. This milestone demonstrates Lupin's unwavering commitment to reducing barriers to treatment and empowering patients with greater choice and confidence in their healthcare journey," said **Dr. Cyrus Karkaria, President, Biotechnology, Lupin**.

Pegfilgrastim 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe had estimated annual sales of $ 1.3 billion in the U.S. for the 12 months ending September 2025.

Lupin gets Positive CHMP Opinion for Biosimilar Ranibizumab

(Lupin) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for its biosimilar ranibizumab, Ranluspec™, for both vial and pre-filled syringe presentations.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), and choroidal neovascularization (CNV).

The positive CHMP opinion is based on a demonstration of similarity to the reference product, including an analytical similarity assessment and a 600-patient global phase III clinical trial in patients with Neovascular AMD, conducted in the US, EU, Russia, and India.

Mr Thierry Volle, President EMEA and Emerging Markets, Lupin, said, "We are very pleased with the CHMP's positive opinion for ranibizumab. This recognition underscores the quality of Lupin's Biologics development and manufacturing as well as our relentless pursuit of affordable solutions that transform patient care."

The CHMP positive opinion will now be considered by the European Commission (EC). Once approved, the EC will grant a centralized marketing authorization for EU member countries. As per the recently announced agreement, Lupin's biosimilar ranibizumab will be commercialized by Sandoz Group AG across the European Union (excluding Germany). In France, the product will be commercialized by two companies, Sandoz AG and Biogaran.

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

Biocon Biologics Ltd (BBL) has announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek™ (ustekinumab injection) and Yesintek™ I.V. (ustekinumab for injection, solution for intravenous infusion), a biosimilar to Stelara® (ustekinumab injection) and Stelara® I.V. (ustekinumab for injection, solution for intravenous infusion). The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October.

YESINTEK and YESINTEK I.V. are indicated for the treatment of moderate to severe plaque psoriasis in adult patients and in pediatric patients (6-17 years of age), active psoriatic arthritis in adults, moderately to severely active Crohn's disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affect thousands of Canadians.
Health Canada approval was based on a comprehensive data package, confirming that YESINTEK is highly similar to Stelara with no clinically meaningful differences in efficacy, safety and immunogenicity. YESINTEK will be available through the **My Biocon Biologics™** patient support program, which provides assistance to individuals prescribed with the therapy. YESINTEK is available as a subcutaneous injection, 45 mg/0.5ml (prefilled syringe and vial) and

90 mg/ml (prefilled syringe) and YESINTEK I.V. as an intravenous solution, 130 mg/26mL (5mg/mL).

***Dr Shreehas Tambe, CEO & Managing Director, Biocon Biologics**, said:* "Health Canada's approval of Yesintek™ marks a significant milestone in our mission to expand global access to high-quality biosimilars. Building on our successful U.S. launch, this approval strengthens our presence in North America and enhances our immunology portfolio with a more affordable treatment option for Canadian patients living with chronic autoimmune conditions."

***Dr Ramy Ayad, Head of Canada at Biocon Biologics**, said:* "We are excited to bring Yesintek™ to Canadian patients, providing a trusted, value-driven ustekinumab biosimilar. Biocon Biologics is committed to advancing biosimilar adoption in Canada to improve outcomes for patients and deliver meaningful savings to the healthcare ecosystem. By expanding access in both public and private markets, we aim to help build a sustainable biosimilars industry that benefits all Canadians."

BioFunding News

Arya.ag raises ₹725 cr in Series D

Noida-based agri-tech firm Arya.ag secured ₹725 crore in a round led by GEF Capital Partners. The funds will drive farmer engagement, climate-smart practices, and expansion of farmgate infrastructure. The company reported ₹300 crore revenue in H1 FY26 and is considering an IPO within two years.

FutureCure Health secures ₹104 cr

Jaipur-based vertigo and dizziness clinic chain FutureCure Health raised ₹104 crore from Carnelian Asset Management and others. The capital will support expansion across hospitals in India and abroad, and entry into chronic lifestyle disease care.

Be Clinical bags ₹6 cr Seed Funding

Delhi skincare startup Be Clinical raised ₹6 crore in seed funding led by V3 Ventures. The investment will strengthen R&D, clinical testing, and manufacturing upgrades for its anti-ageing product line.

Sensa Core attracts $72million Investment

Hyderabad medical diagnostics manufacturer Sensa Core received ₹650 crore ($72M) from Motilal Oswal Alternates. The funds will accelerate product development and expand its global footprint in IVD devices.

Elmentoz Research raises $4.5M

Bhubaneswar biotech startup Elmentoz Research has secured $4.5M from Indian and Norwegian angels. The company is building a BSF-based protein facility and expanding product lines in animal nutrition.

Supply6 gains backing from Actor Kriti Sanon

Bengaluru based direct to consumer nutrition brand Supply6 received investment from actor Kriti Sanon. Its flagship sachet Supply6 360 addresses nutrient deficiencies, with distribution across e-commerce and quick commerce platforms in India and the US.

Aurobindo Pharma subsidiary ups JV stake inChinese firm

Helix Healthcare B.V., a unit of Aurobindo Pharma, increased its stake to 50% in Chinese JV Luoxin Aurovitas with a $5.12M investment. Full ownership is possible by 2029.

Lemnisca raises pre-seed round from Theia Ventures

Bengaluru based bio-manufacturing startup Lemnisca has raised a pre-seed round led by Theia Ventures. The company is developing AI-driven systems to scale sustainable bioproduction, including an AI companion for fermentation.

BioEnergy Highlights

India become first country to commercially produce bio-bitumen

Road, Transport and Highways Minister Mr Nitin Gadkari has said that India has become the first country in the world to commercially produce bio-bitumen in road construction. Bitumen is a black, viscous mixture of hydrocarbons produced by the fractionation of crude oil, and it serves as a crucial binder in road construction.

While addressing the CSIR Technology Transfer Ceremony "Bio-Bitumen via Pyrolysis: From Farm Residue to Roads", in New Delhi, the Minister congratulated CSIR on this historic milestone. Mr Gadkari said that the initiative will help in reducing pollution from crop residue burning. The Minister said that bio-bitumen is a transformative step towards the vision of Viksit Bharat 2047. The technology has been developed jointly by two research laboratories under CSIR, the Central Road Research Institute, New Delhi and the Indian Institute of Petroleum, Dehradun.

The shift to indigenous bio-bitumen holds economic potential of replacing imported bitumen worth ₹25,000–30,000 crore annually.

Speaking on this occasion, Science and Technology Minister Dr Jitendra Singh said that by achieving this milestone, India has entered into a new era of clean and green highways. He said that the initiative will also aid the Waste to Wealth mission and support the country's vision of Atma Nirbhar Bharat.

"This day will go down in the history as India enters into an era of 'Clean, Green Highways', with the successful Technology Transfer titled an indigenous innovation developed by two CSIR laboratories," Dr Singh said.

This was stated here today by Union Minister of State (Independent Charge) for Science & Technology, Earth Sciences, and Vice-President, CSIR, Dr Jitendra Singh, while addressing the Technology Transfer ceremony titled "Bio-Bitumen via Pyrolysis: From Farm Residue to Roads".

Dr Jitendra Singh said, the day would be remembered as a historic milestone, stating that India's highways are now transitioning from fossil-fuel dependency to bio-driven, regenerative, and circular economy solutions. The roads constructed using this technology will involve lesser budget, have a more sustainable lifespan, and will also be free from the hazard of causing environmental pollution.

India is now commercially producing bio-bitumen for use as an alternative to traditional asphalt in the construction of roadways. By utilizing agricultural waste and organic waste products, the bio-bitumen has been developed from materials that were previously discarded. This initiative supports India's commitment to increasing the use of sustainable building materials and creating a circular economic model that will eliminate reliance on fossil fuels while reducing carbon emissions related to road construction.

Studies indicate that bio-bitumen had achieved successful evaluations concerning its performance and durability; consequently, bio-bitumen will now be used in the construction of roads.

It is anticipated that this innovation will result in increased cost-effectiveness, enhanced environmental conditions, and the ability to value-add to agricultural waste streams. As such, the introduction of bio-bitumen supports numerous national programs associated with Green Infrastructure, Waste to Wealth initiatives, and Sustainable Mobility.

Essar Energy to invest of ₹5,100 crore in biofuel plant in Gujarat

Future Energy Limited has announced a strategic investment of **₹5,100 crore** to establish a large-scale greenfield bio-fuel complex in Gujarat's **Devbhumi Dwarka** district.
Located near **Kajurda village** in the Khambhaliya region, the project marks a significant step in the Essar Group's shift toward cleaner energy infrastructure, aligning with India's expanding low-carbon fuel roadmap.

Designed to process **1 million tonnes of feedstock annually** in its initial phase, the complex will utilise biogenic waste streams including **used cooking oil (UCO)** and **palm oil mill effluent (POME)**.

The company formalized the commitment by signing a **Memorandum of Understanding (MoU)** with the Government of Gujarat during a Vibrant Gujarat-linked regional investment event held in Rajkot in early January 2026. Essar said the facility is expected to generate **around 350 direct jobs**, with commercial operations targeted to begin by **2029**.

The facility is planned as an **export-oriented unit**, strengthening Gujarat's ambition to become a manufacturing base for advanced green fuels that can serve both domestic blending requirements and global demand.

The complex will focus on three primary products:

- **Sustainable Aviation Fuel (SAF):** to support aviation decarbonisation
- **Hydrotreated Vegetable Oil (HVO):** a renewable diesel alternative for road transport and shipping
- **Bio-naphtha:** a greener feedstock for petrochemical and refining applications

Commenting on the development, **Mr. Vibhav Agarwal**, CEO of Essar Future Energy Limited, said the project aligns with Gujarat's long-term industrial and sustainability priorities. "This initiative is aligned with the vision of 'Viksit Gujarat – Viksit Bharat @ 2047'," Mr Agarwal said. "We are proud to partner with the state to develop future-ready, low-carbon energy solutions that support both industrial growth and global sustainability."
The MoU was exchanged in the presence of senior Gujarat government leaders and officials from the Energy & Petrochemicals Department, signalling strong backing for the state's growing clean-fuels ecosystem.

Ethanol blending hits 20% in November 2025

India is steadily advancing in the ethanol sector, with both production and blending levels rising each year and manufacturing capacity expanding. This progress is reshaping the nation's energy landscape while boosting economic development and promoting sustainable growth in rural areas.

During the current Ethanol Supply Year (ESY) 2025–26, ethanol blending in petrol reached 20 per cent in November 2025. In the same month, Oil Marketing Companies (OMCs) received 45.5 crore litres of ethanol under the Ethanol Blended Petrol (EBP) Programme. Official data indicates that a total of 89.6 crore litres of ethanol was blended into petrol in November 2025.

In the previous ESY 2024–25, OMCs blended 1,022.8 crore litres of ethanol, achieving a average blending level of 19.2 per cent. This accelerated progress has helped reduce dependence on imported crude oil, resulting in significant foreign exchange savings and strengthening India's transition towards a cleaner and more self-reliant energy future.

The OMCs have allocated around 1,048 crore litres of ethanol against 1,776 crore litres of offers submitted by manufacturers across the country for ESY 2025–26 (Cycle 1). OMCs had invited tenders for the supply of 1,050 crore litres of ethanol for ESY 2025–26.

In the allocation, maize holds the largest share at 45.68 per cent (around 478.9 crore litres), followed by FCI rice at 22.25 per cent (around 233.3 crore litres), sugarcane juice at 15.82 per cent (around 165.9 crore litres), B-heavy molasses at 10.54 per cent (around 110.5 crore litres), damaged food grains at 4.54 per cent (around 47.6 crore litres), and C-heavy molasses at 1.16 per cent (around 12.2 crore litres).

Currently, India's total ethanol production capacity as of November 2025 is about 1,990 crore litres, and the industry is calling for an increase in ethanol blending beyond 20 per cent, stating that capacities are underutilised.
(Courtesy: www.chinimandi.com)

BPCL flags off first tanker of 1G bio-ethanol from Bargarh Refinery

BPCL flags off its first 1G Bio-Ethanol tanker lorry

State-owned Bharat Petroleum Corporation Limited (BPCL) has flagged off its first-ever tanker lorry carrying domestically produced 1G Bio-Ethanol from the Bargarh Bio-Refinery to the IOTL Raipur Depot. The event was marked by Mr Sanjay Khanna, Director (Refineries) and holding additional charge as Chairman & Managing Director of BPCL.

BPCL has been actively expanding its bio-refinery capabilities in recent years, as part of the government mandates on renewable fuels. The commissioning of the Bargarh Bio-Refinery and the first shipment of BPCL-produced 1G ethanol mark a significant step in the nation's journey toward a Viksit Bharat, where domestic renewable energy plays a central role in growth and sustainability.

During his visit, Khanna reviewed the bio-refinery facilities and commended the dedicated efforts of the project and operations teams, whose coordinated execution enabled this milestone. He emphasized BPCL's continued commitment to innovation, sustainability, and energy security, reinforcing the company's role in India's long-term economic and environmental development.

---

bp, Corteva Launch Biofuel Feedstock Platform

Energy giant bp and global agriculture technology company Corteva have announced the launch of Etlas, a new 50:50 joint venture aimed at producing seed-based feedstock for biofuels such as sustainable aviation fuel (SAF) and renewable diesel (RD).

A statement by the companies said the new platform aims to provide a reliable and scalable feedstock source as demand for biofuels is expected to grow rapidly over the next few years, with SAF demand anticipated to scale from approximately 1 million tonnes in 2024 to as much as 10 million tonnes by 2030, and for RD demand to double over the same period to 35 million tonnes.

The new platform will produce oil from crops such as sunflower, mustard and canola, to be used in the production of biofuels, combining Corteva's expertise in seed technology to develop crops ideally suited to produce SAF and RD, and bp's expertise in refining and marketing fuel for the commercial transportation market.

Etlas will be led by Corteva's Global Business Development Director, Mr Ignacio Conti, as CEO, and Mr Gaurav Sonar, Vice President of Novel Feedstocks at bp as Chair of the Board of Directors.

According to bp and Corteva, the new platform aims to begin supplying feedstock for biofuels in 2027, and to produce one million metric tonnes of feedstock per year by the mid-2030s, which could produce over 800 thousand tonnes of biofuel.
(Courtesy: EPG Today)

TruAlt, Sumitomo to collaborate to produce Compressed Biomethane Gas (CBG) in India

Sumitomo Corporation (Head Office: Chiyoda-ku, Tokyo; Representative Director, President and Chief Executive Officer: Shingo Ueno) has agreed, as of November 11, 2025, to acquire a portion of the shares of TruAlt Gas Private Limited (Head Office: Bengaluru, India; Managing Director and CEO: Vijay Murugesh Nirani; hereinafter "TGPL"), a subsidiary of TruAlt Bioenergy Limited (hereinafter "TruAlt"), India's largest ethanol manufacturing company and to enter into a strategic collaboration with TruAlt.

Japan based Sumitomo Corporation has agreed to acquire a portion of the shares of Bengaluru-based TruAlt Gas Pvt Ltd, a subsidiary of TruAlt BioEnergy and enter into a strategic collaboration with the Indian company.

The new joint venture company, to be called TruAlt Sumi Gas Pvt Ltd, aims to construct 16 compressed biomethane gas (CBG) production facilities across India over the next three years and commence operations sequentially from 2026. The total daily production capacity of the 16 facilities is expected to reach approximately 320 tons, equivalent to the daily gas consumption of around 800,000 households in India.

The raw materials for CBG production will include sugarcane and ethanol residue at TruAlt and other suppliers. The CBG produced will primarily be sold as automobile fuel to major city gas distributors within India. Alongside CBG production, Sumitomo Corporation and TruAlt also plan to collaborate on expanding bioethanol production and producing sustainable aviation fuel (SAF) derived from bioethanol.

Photo of Signing ceremony

From left Hiroshi Horii, General Manager, Biomass Energy Business Unit, Sumitomo Corporation; Hirokazu Higashino, General Manager for Asia & Oceania, Sumitomo Corporation; Yasushi Yoshida, Duputy General Manager, Energy Innovation Initiative SBU, Sumitomo Corporation; Vijay Murugesh Nirani, Founder, CEO and Managing Director, TruAlt; Dr Murugesh Nirani, Founder, Nirani Sugars; Sushmitha Nirani, Non-Executive Director, TruAlt; Y. B. Ramakrishna, Independent Director, TruAlt.

ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES (ABLE)

Comments and questions are welcome and should be addressed to:

Email
coo@ableindia.org.in

Website
www.ableindia.in

Twitter

LinkedIn

Address
No.123/C, 16th Main Road 4th Block, 5th Cross, Koramangala, Bangalore-560 034, India

Tel.:
+91-80-41636853

able
Pursuing Infinite Opportunities
Association of Biotechnology Led Enterprises

FOCUS AREAS

www.ableindia.in